Related references
Note: Only part of the references are listed.A Phase IIb Dose-Ranging Study of the Oral JAK Inhibitor Tofacitinib (CP-690,550) Versus Placebo in Combination With Background Methotrexate in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2012)
Antiinflammatory Functions of p38 in Mouse Models of Rheumatoid Arthritis Advantages of Targeting Upstream Kinases MKK-3 or MKK-6
Monica Guma et al.
ARTHRITIS AND RHEUMATISM (2012)
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
Roy Fleischmann et al.
ARTHRITIS AND RHEUMATISM (2012)
Novel small-molecular therapeutics for rheumatoid arthritis
Roy Fleischmann
CURRENT OPINION IN RHEUMATOLOGY (2012)
Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis
Emma Leah
Nature Reviews Rheumatology (2012)
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
Roy Fleischmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2011)
Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis
David L. Scott
DRUGS (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
RHEUMATOID ARTHRITIS Circadian and circannual rhythms in RA
Maurizio Cutolo
NATURE REVIEWS RHEUMATOLOGY (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phase II Study of Tofacitinib (CP-690,550) Combined With Methotrexate in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Yoshiya Tanaka et al.
ARTHRITIS CARE & RESEARCH (2011)
Novel therapeutics - exciting gifts but how best to use them? Preface
I. B. McInnes et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
Richard J. Riese et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Evaluation of the Efficacy and Safety of Pamapimod, a p38 MAP Kinase Inhibitor, in a Double-Blind, Methotrexate-Controlled Study of Patients With Active Rheumatoid Arthritis
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2009)
Efficacy, Pharmacodynamics, and Safety of VX-702, a Novel p38 MAPK Inhibitor, in Rheumatoid Arthritis Results of Two Randomized, Double-Blind, Placebo-Controlled Clinical Studies
Nemanja Damjanov et al.
ARTHRITIS AND RHEUMATISM (2009)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Kamran Ghoreschi et al.
NATURE IMMUNOLOGY (2009)
Treatment of Rheumatoid Arthritis With a Syk Kinase Inhibitor A Twelve-Week, Randomized, Placebo-Controlled Trial
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2008)
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman et al.
NATURE BIOTECHNOLOGY (2008)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Role of mitogen-activated protein kinase kinase kinases in signal integration
B. D. Cuevas et al.
ONCOGENE (2007)
Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
M Pesu et al.
IMMUNOLOGICAL REVIEWS (2005)
A new modality for immunosuppression: Targeting the JAK/STAT pathway
JJ O'Shea et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
The Janus kinases (Jaks)
K Yamaoka et al.
GENOME BIOLOGY (2004)
Role of Jak kinases and STATS in cytokine signal transduction
WJ Leonard
INTERNATIONAL JOURNAL OF HEMATOLOGY (2001)
Cytokine receptor signaling pathways
WJ Leonard et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
Share Paper
